Valeant To Acquire Salix Pharmaceuticals in a Deal Worth About $14.5 Billion

Valeant To Acquire Salix Pharmaceuticals in a Deal Worth About $14.5 Billion Valeant Pharmaceuticals International and Salix Pharmaceuticals announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158 per share in cash or a tota...

Full Story →